Thursday Is Your Last Chance To Buy Bio-Techne Before The Dividend Payout 2023/02/07 14:45:50 Benzinga
Thursday marks the last chance for investors to receive the next dividend payout from Bio-Techne (NASDAQ: TECH ). What''s Happening The company announced on Thursday that it would pay shareholders a quarterly dividend of 8 cents per share. On Friday, Bio-Techne will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will … Full story available on Benzinga.com
Bio-Techne Corp. PT Lowered to $100 at Craig-Hallum 2023/02/03 14:46:11 Investing.com
Bio-Techne Corporation (TECH) Q2 2023 Earnings Call Transcript 2023/02/02 16:51:02 Seeking Alpha
Bio-Techne Corporation (NASDAQ:NASDAQ:TECH) Q2 2023 Earnings Conference Call February 2, 2023 9:00 AM ETCompany ParticipantsDavid Clair - Vice President of Investor RelationsChuck Kummeth -…
Bio-Techne declares $0.08 dividend 2023/02/02 11:46:40 Seeking Alpha
Bio-Techne (NASDAQ:TECH) declares $0.08/share quarterly dividend, in-line with prior dividend of $0.32 (adjusting for 4 for 1 stock split).Forward yield 0.39%Payable Feb.
Bio-Techne GAAP EPS of $0.31 misses by $0.03, revenue of $271.58M misses by $18.15M 2023/02/02 11:36:07 Seeking Alpha
Bio-Techne press release (TECH): Q2 GAAP EPS of $0.31 misses by $0.03.Revenue of $271.58M (+0.9% Y/Y) misses by $18.15M.
Bio-techne Corp Common Stock TECH Trading Signals 2023/01/04 09:45:00 Stock Traders Daily
Buy and Sell Signals for Bio-techne Corp Common Stock TECH that help investors manage their investment in TECH
BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 2022/12/21 12:00:00 PR Newswire
MINNEAPOLIS, Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 8:15 a.m. PST. A live webcast of…
Stem Cell Assay Global Market Report 2022: Ukraine-Russia War Impact 2022/12/12 11:33:00 GlobeNewswire
Major players in the stem cell assay market are Thermo Fisher Scientific Inc. , Merck Group, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, PerkinElmer, Agilent Technologies, Promega Biotechnology Company, Cell Biolabs, Miltenyi Biotec, STEMCELL Technologies, Bio-Techne Corporation, Charles River Laboratories International Inc. Major players in the stem cell assay market are Thermo Fisher Scientific Inc. , Merck Group, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, PerkinElmer, Agilent Technologies, Promega Biotechnology Company, Cell Biolabs, Miltenyi Biotec, STEMCELL Technologies, Bio-Techne Corporation, Charles River Laboratories International Inc.
RBC Capital Starts Bio-Techne Corp. at Sector Perform 2022/12/06 21:30:12 Investing.com
Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer 2022/07/06 15:15:49 Seeking Alpha
Bio-Techne (TECH) said it launched the CE-IVD marked RNAscope ISH Probe High Risk HPV test in Europe for use in throat cancer.The test is intended for use in patients diagnosed…
Bio-Techne to acquire single-cell sorting platform provider Namocell 2022/06/22 12:19:13 Seeking Alpha
Bio-Techne (TECH) is acquiring Mountain View, Calif.-based Namocell.Financial terms of the deal were not disclosed the company''s June 22 press release.Namocell provides single cell…
Tackling Recurring Health Conditions Offers Hope to Patients 2022/06/21 15:00:00 Benzinga
FinancialNewsMedia.com News Commentary PALM BEACH, FL , June 21, 2022 /PRNewswire/ -- Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly in the case of cancer or heart conditions. This reality is encouraging more companies to seek treatments for recurring conditions. Here we discuss companies treating recurring health conditions in reference to Merck (NYSE: MRK ), Bio-Techne Corporation (NASDAQ: TECH ), Natera (NASDAQ: NTRA ) and Cardiol Therapeutics (NASDAQ: CRDL ) (TSX: CRDL ). Triple-negative breast cancer is the most aggressive type of breast cancer, with the highest risk of recurrence within the first five years after diagnosis. Merck (NYSE: MRK ) just had its drug KEYTRUDA® (pembrolizumab) plus chemotherapy approved by the European Commission to treat locally advanced or early-stage triple-negative breast cancer at high risk of recurrence. This offers enormous encouragement to those suffering from this devastating condition.
Baron Funds: “Bio-Techne (TECH) Can Still Generate Strong Revenue Growth” 2022/06/15 12:26:45 Insider Monkey
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.